Search

Your search keyword '"Grove, Lorna"' showing total 21 results
Start Over Author "Grove, Lorna"
21 results on '"Grove, Lorna"'

1. Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent adjuvant immunotherapy

Author

Patin, Emmanuel C., Nenclares, Pablo, Chan Wah Hak, Charleen, Dillon, Magnus T., Patrikeev, Anton, McLaughlin, Martin, Grove, Lorna, Foo, Shane, Soliman, Heba, Barata, Joao P., Marsden, Joanna, Baldock, Holly, Gkantalis, Jim, Roulstone, Victoria, Kyula, Joan, Burley, Amy, Hubbard, Lisa, Pedersen, Malin, Smith, Simon A., Clancy-Thompson, Eleanor, Melcher, Alan A., Ono, Masahiro, Rullan, Antonio, and Harrington, Kevin J.

Published
2024
Full Text
View/download PDF

2. Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation

Author

Dillon, Magnus T., Guevara, Jeane, Mohammed, Kabir, Patin, Emmanuel C., Smith, Simon A., Dean, Emma, Jones, Gemma N., Willis, Sophie E., Petrone, Marcella, Silva, Carlos, Thway, Khin, Bunce, Catey, Roxanis, Ioannis, Nenclares, Pablo, Wilkins, Anna, McLaughlin, Martin, Jayme-Laiche, Adoracion, Benafif, Sarah, Nintos, Georgios, Kwatra, Vineet, Grove, Lorna, Mansfield, David, Proszek, Paula, Martin, Philip, Moore, Luiza, Swales, Karen E., Banerji, Udai, Saunders, Mark P., Spicer, James, Forster, Martin D., and Harrington, Kevin J.

Subjects
Tumors -- Drug therapy -- Genetic aspects, Inflammation -- Drug therapy -- Genetic aspects, Health care industry
Abstract

BACKGROUND. Phase 1 study of ATR inhibition alone or with radiation therapy (PATRIOT) was a first-in-human phase I study of the oral ATR (ataxia telangiectasia and Rad3-related) inhibitor ceralasertib (AZD6738) in advanced solid tumors. METHODS. The primary objective was safety. Secondary objectives included assessment of antitumor responses and pharmacokinetic (PK) and pharmacodynamic (PD) studies. Sixty-seven patients received 20-240 mg ceralasertib BD continuously or intermittently (14 of a 28-day cycle). RESULTS. Intermittent dosing was better tolerated than continuous, which was associated with dose-limiting hematological toxicity. The recommended phase 2 dose of ceralasertib was 160 mg twice daily for 2 weeks in a 4-weekly cycle. Modulation of target and increased DNA damage were identified in tumor and surrogate PD. There were 5 (8%) confirmed partial responses (PRs) (40-240 mg BD), 34 (52%) stable disease (SD), including 1 unconfirmed PR, and 27 (41%) progressive disease. Durable responses were seen in tumors with loss of AT-rich interactive domain-containing protein 1A (ARID1A) and DNA damageresponse defects. Treatment-modulated tumor and systemic immune markers and responding tumors were more immune inflamed than nonresponding. CONCLUSION. Ceralasertib monotherapy was tolerated at 160 mg BD intermittently and associated with antitumor activity. TRIAL REGISTRATION. Clinicaltrials.gov: NCT02223923, EudraCT: 2013-003994-84. FUNDING. Cancer Research UK, AstraZeneca, UK Department of Health (National Institute for Health Research), Rosetrees Trust, Experimental Cancer Medicine Centre., Introduction ATR (ataxia telangiectasia and Rad3-related) is a critical kinase in the DNA damage response (DDR) (1, 2). Preclinical data have identified multiple cancer-related phenotypes sensitizing tumor cells to monotherapy [...]

Published
2024
Full Text
View/download PDF

3. Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent anti-PD-L1- and anti-NKG2A-based adjuvant immunotherapy

Author

Patin, Emmanuel Christian, primary, Nenclares, Pablo, additional, Chan Wah Hak, Charleen, additional, Dillon, Magnus T, additional, Patrikeev, Anton, additional, McLaughlin, Martin, additional, Grove, Lorna, additional, Foo, Shane, additional, Soliman, Heba, additional, Barata, Joao P, additional, Marsden, Joanna, additional, Baldock, Holly, additional, Roulstone, Victoria, additional, Kyula, Joan, additional, Burley, Amy, additional, Hubbard, Lisa C, additional, Pedersen, Malin, additional, Smith, Simon A, additional, Clancy-thompson, Eleanor, additional, Melcher, Alan A, additional, Ono, Masahiro, additional, Rullan, Antonio, additional, and Harrington, Kevin J, additional

Published
2023
Full Text
View/download PDF

5. Figure S2A from Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study

Author

Dillon, Magnus T., primary, Grove, Lorna, primary, Newbold, Kate L., primary, Shaw, Heather, primary, Brown, Nicholas F., primary, Mendell, Jeanne, primary, Chen, Shuquan, primary, Beckman, Robert A., primary, Jennings, Anne, primary, Ricamara, Marivic, primary, Greenberg, Jonathan, primary, Forster, Martin, primary, and Harrington, Kevin J., primary

Published
2023
Full Text
View/download PDF

6. Supplementary Data from Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study

Author

Dillon, Magnus T., primary, Grove, Lorna, primary, Newbold, Kate L., primary, Shaw, Heather, primary, Brown, Nicholas F., primary, Mendell, Jeanne, primary, Chen, Shuquan, primary, Beckman, Robert A., primary, Jennings, Anne, primary, Ricamara, Marivic, primary, Greenberg, Jonathan, primary, Forster, Martin, primary, and Harrington, Kevin J., primary

Published
2023
Full Text
View/download PDF

8. Harnessing radiotherapy-induced NK-cell activity by combining DNA damage–response inhibition and immune checkpoint blockade

Author

Patin, Emmanuel C, primary, Dillon, Magnus T, additional, Nenclares, Pablo, additional, Grove, Lorna, additional, Soliman, Heba, additional, Leslie, Isla, additional, Northcote, Davina, additional, Bozhanova, Galabina, additional, Crespo-Rodriguez, Eva, additional, Baldock, Holly, additional, Whittock, Harriet, additional, Baker, Gabriella, additional, Kyula, Joan, additional, Guevara, Jeane, additional, Melcher, Alan A, additional, Harper, James, additional, Ghadially, Hormas, additional, Smith, Simon, additional, Pedersen, Malin, additional, McLaughlin, Martin, additional, and Harrington, Kevin J, additional

Published
2022
Full Text
View/download PDF

9. Combination therapy with oncolytic viruses and immune checkpoint inhibitors

Author

Chiu, Matthew, primary, Armstrong, Edward John Lloyd, additional, Jennings, Vicki, additional, Foo, Shane, additional, Crespo-Rodriguez, Eva, additional, Bozhanova, Galabina, additional, Patin, Emmanuel Christian, additional, McLaughlin, Martin, additional, Mansfield, David, additional, Baker, Gabriella, additional, Grove, Lorna, additional, Pedersen, Malin, additional, Kyula, Joan, additional, Roulstone, Victoria, additional, Wilkins, Anna, additional, McDonald, Fiona, additional, Harrington, Kevin, additional, and Melcher, Alan, additional

Published
2020
Full Text
View/download PDF

10. The effect of parotid gland-sparing IMRT on salivary composition, flow rate and xerostomia measures

Author

Richards, Thomas M, Hurley, Tara, Grove, Lorna, Harrington, Kevin J, Carpenter, Guy H, Proctor, Gordon B, and Nutting, Christopher M

Subjects
Adult, Male, Organs at Risk, Middle Aged, Radiation Dosage, Xerostomia, Article, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Head and Neck Neoplasms, Humans, Parotid Gland, Female, Radiotherapy, Intensity-Modulated, Saliva, Organ Sparing Treatments, Aged
Abstract

To describe parotid gland (PG) saliva organic and inorganic composition and flow rate changes, after curative intensity-modulated radiotherapy (IMRT) for head and neck cancer (HNC), and analyse the relationship between PG saliva analytes and xerostomia measures.Twenty-six patients recruited to five prospective phase 2 or 3 trials which assessed toxicity and efficacy of IMRT by HNC subsite, provided longitudinal PG saliva. Salivary flow rate, and subjective and objective xerostomia measures were prospectively collected and saliva tested for inorganic and organic analytes. Statistical comparisons of longitudinal analyte changes and analysis for a relationship between dichotomized xerostomia score and saliva analytes were performed.One hundred and forty-two PG saliva samples from 26 patients were analysed. At 3-6 months after IMRT, stimulated and unstimulated saliva showed significantly decreased flow rate, total protein (TP) secretion rate, phosphate concentration and increased lactoferrin (LF) concentration. Stimulated saliva alone had elevated LF secretion rate and beta-2-microglobulin (BFewer significant differences in PG saliva analytes12 months after IMRT indicate good functional recovery. Residual xerostomia after IMRT will only be further reduced by addressing the sparing of subsites of the PG or other salivary gland tissues, in addition to the PG.

Published
2017

11. Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study

Author

Dillon, Magnus T., primary, Grove, Lorna, additional, Newbold, Kate L., additional, Shaw, Heather, additional, Brown, Nicholas F., additional, Mendell, Jeanne, additional, Chen, Shuquan, additional, Beckman, Robert A., additional, Jennings, Anne, additional, Ricamara, Marivic, additional, Greenberg, Jonathan, additional, Forster, Martin, additional, and Harrington, Kevin J., additional

Published
2019
Full Text
View/download PDF

12. A practical guide to the handling and administration of talimogene laherparepvec in Europe

Author

Harrington, Kevin J, Michielin, Olivier, Malvehy, Josep, Grove, Lorna, Frauchiger, Anna Lisa, Dummer, Reinhard, University of Zurich, and Harrington, Kevin J

Subjects
practical considerations, talimogene laherparepvec, intralesional injection, melanoma, 10177 Dermatology Clinic, 2736 Pharmacology (medical), 610 Medicine & health, 2730 Oncology, oncolytic immunotherapy, herpes simplex virus
Published
2017

13. Predicting response to radical (chemo)radiotherapy with circulating HPV DNA in locally advanced head and neck squamous carcinoma

Author

Lee, Jen Y, primary, Garcia-Murillas, Isaac, additional, Cutts, Rosalind J, additional, De Castro, David Gonzalez, additional, Grove, Lorna, additional, Hurley, Tara, additional, Wang, Fuqiang, additional, Nutting, Christopher, additional, Newbold, Katie, additional, Harrington, Kevin, additional, Turner, Nicholas, additional, and Bhide, Shreerang, additional

Published
2017
Full Text
View/download PDF

15. Abstract CT084: A Phase I dose-escalation study of ATR inhibitor monotherapy with AZD6738 in advanced solid tumors (PATRIOT Part A)

Author

Dillon, Magnus T., primary, Espinasse, Aude, additional, Ellis, Sally, additional, Mohammed, Kabir, additional, Grove, Lorna G., additional, McLellan, Lyndall, additional, Smith, Simon A., additional, Ross, Graham, additional, Adeleke, Sola, additional, Woo, Kin, additional, Josephides, Eleni, additional, Spicer, James F., additional, Forster, Martin D., additional, and Harrington, Kevin J., additional

Published
2017
Full Text
View/download PDF

16. Predicting response to radical (chemo)radiotherapy (R-CRT) with circulating HPV DNA and tumor DNA (ctDNA) analysis in locally-advanced head and neck squamous cell carcinoma (LAHNC).

Author

Bhide, Shreerang, primary, Lee, Jen, additional, Garcia-Murillas, Isaac, additional, Cutts, Ros, additional, Hurley, Tara, additional, Grove, Lorna, additional, Nutting, Christopher, additional, Newbold, Kate, additional, Turner, Nicholas C., additional, and Harrington, Kevin, additional

Published
2017
Full Text
View/download PDF

17. A practical guide to the handling and administration of talimogene laherparepvec in Europe

Author

Harrington,Kevin, Michielin,Olivier, Malvehy,Josep, Pezzani Grüter,Isabella, Grove,Lorna, Frauchiger,Anna Lisa, Dummer,Reinhard, Harrington,Kevin, Michielin,Olivier, Malvehy,Josep, Pezzani Grüter,Isabella, Grove,Lorna, Frauchiger,Anna Lisa, and Dummer,Reinhard

Abstract

Kevin J Harrington,1 Olivier Michielin,2 Josep Malvehy,3,4 Isabella Pezzani Grüter,5 Lorna Grove,6 Anna Lisa Frauchiger,7 Reinhard Dummer7 1NIHR Biomedical Research Centre, The Institute of Cancer Research/The Royal Marsden Hospital, London, UK; 2Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; 3Hospital Clinic de Barcelona, IDIBAPS, CIBER de enfermedades raras, Barcelona, Spain; 4FIS del Instituto de Salud Carlos III, Madrid, Spain; 5Department of Research and Development, Amgen Switzerland AG, Zug, Switzerland; 6Head and Neck Unit, The Royal Marsden Hospital, London, UK; 7Skin Cancer Centre/Dermatology Clinic, Universitätsspital Zürich, Zurich, Switzerland Abstract: Talimogene laherparepvec is a herpes simplex virus-1-based intralesional oncolytic immunotherapy and is the first oncolytic virus to be approved in Europe. It is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (stage IIIB, IIIC, and IVM1a) with no bone, brain, lung, or other visceral disease. Talimogene laherparepvec is a genetically modified viral therapy, and its handling needs special attention due to its deep freeze, cold-chain requirements, its potential for viral shedding, and its administration by direct intralesional injection. This review provides a practical overview of handling, storage, and administration procedures for this agent in Europe. Talimogene laherparepvec vials should be transported/stored frozen at a temperature of –90°C to –70°C, and once thawed, vials must not be refrozen. Universal precautions for preparation, administration, and handling should be followed to avoid accidental exposure. Health care providers should wear personal protective equipment, and materials that come into contact with talimogene laherparepvec should be disposed of in accordance with local institutional procedures. Individuals who are

Published
2017

18. Blood transfusion during radical chemo-radiotherapy does not reduce tumour hypoxia in squamous cell cancer of the head and neck

Author

Welsh, Liam, primary, Panek, Rafal, additional, Riddell, Angela, additional, Wong, Kee, additional, Leach, Martin O, additional, Tavassoli, Mahvash, additional, Rahman, Durdana, additional, Schmidt, Maria, additional, Hurley, Tara, additional, Grove, Lorna, additional, Richards, Thomas, additional, Koh, Dow-Mu, additional, Nutting, Christopher, additional, Harrington, Kevin, additional, Newbold, Kate, additional, and Bhide, Shreerang, additional

Published
2016
Full Text
View/download PDF

19. PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours.

Author

Dillon, Magnus, primary, Ellis, Sally, additional, Grove, Lorna, additional, McLellan, Lyndall, additional, Clack, Glen, additional, Smith, Dr Simon, additional, Laude, Jennifer, additional, Viney, Zaid, additional, Adeleke, Sola, additional, Lazaridis, George, additional, Spicer, James F., additional, Forster, Martin David, additional, and Harrington, Kevin J., additional

Published
2016
Full Text
View/download PDF

20. Patritumab (P) or placebo (PBO) plus cetuximab (C) and platinum-based therapy in squamous cell carcinoma of the head and neck (SCCHN): a phase 2 study.

Author

Harrington, Kevin J., primary, Forster, Martin David, additional, Dillon, Magnus, additional, Grove, Lorna, additional, Adeleke, Sola, additional, Chen, Shuquan, additional, Diamond, Jane S., additional, Hannus, Henrik, additional, Cooper, Kandance, additional, and Greenberg, Jonathan, additional

Published
2016
Full Text
View/download PDF

21. Blood transfusion during radical chemo-radiotherapy does not reduce tumour hypoxia in squamous cell cancer of the head and neck.

Author

Welsh, Liam, Panek, Rafal, Riddell, Angela, Wong, Kee, Leach, Martin O, Tavassoli, Mahvash, Rahman, Durdana, Schmidt, Maria, Hurley, Tara, Grove, Lorna, Richards, Thomas, Koh, Dow-Mu, Nutting, Christopher, Harrington, Kevin, Newbold, Kate, and Bhide, Shreerang

Subjects
CANCER treatment, BLOOD transfusion, CLINICAL trials, COMPARATIVE studies, LONGITUDINAL method, MAGNETIC resonance imaging, HEAD tumors, RESEARCH methodology, MEDICAL cooperation, METASTASIS, RESEARCH, NECK tumors, RESEARCH funding, SQUAMOUS cell carcinoma, EVALUATION research, DIAGNOSIS, TUMOR treatment
Abstract

Background: Patients with head and neck squamous cell carcinoma (HNSCC) undergoing radical chemo-radiation (CRT) frequently receive transfusion with packed red cells (PRCT) during radiotherapy on the basis that PRCT increases tumour oxygenation and overcomes hypoxia-induced radio-resistance. This is likely to be a significant oversimplification given the fact that tumour hypoxia is the result of several intrinsic and extrinsic factors, including many that are not directly related to serum haemoglobin (Hb). Therefore, we have studied the effect of PRCT on tumour oxygenation in a prospective cohort of patients who developed low Hb during radical CRT for HNSCC.Methods: This was a prospective study of 20 patients with HNSCC receiving radical CRT undergoing PRCT for Hb<11.5 g dl-1. Patients underwent pretransfusion and posttransfusion intrinsic susceptibility-weighted (SWI) MRI and dynamic contrast-enhanced (DCE) MRI. Blood samples were obtained at the time of MRI scanning and two further time points for measuring Hb and a panel of serum cytokine markers of tumour hypoxia. 3D T2* and Ktrans maps were calculated from the MRI data for primary tumours and cervical lymph node metastases.Results: PRCT produced no change (11 patients) or reduced (1 patient) T2* (tumour oxygenation) in 12 of the 16 (75%) evaluable primary tumours. Three of the four patients with improved tumour oxygenation progressed or had partial response following treatment completion. There were variable changes in Ktrans (tumour perfusion or vessel permeability) following PRCT that were of small magnitude for most tumours. Pre- and Post-PRCT levels of measured cytokines were not significantly different.Conclusions: This study suggests that PRCT during radical CRT for HNSCC does not improve tumour oxygenation. Therefore, oncologists should consider changing practice according to NICE and American Association of Blood Banks guidelines on PRCT for anaemia. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results